EGFR and non-small cell lung carcinoma: A phase 3 trial (FLAURA) in EGFR T790M-mutated NSCLC compared first-line osimertinib 80 mg once daily to standard-of-care gefitinib 250 mg or erlotinib 150 mg once daily.